Investigating how specific tumor markers affect lung cancer treatment responses

Who could benefit from this research

What this research studies

This research focuses on non-small cell lung cancer (NSCLC) and aims to understand how certain genetic markers, known as motif neoepitopes, influence the effectiveness of PD-1 inhibitors, a type of immunotherapy. By analyzing tumor samples from patients with specific HLA-B44 alleles, the study will explore the tumor microenvironment and how it varies between patients with and without these markers. The approach includes examining gene expression and cellular composition to identify potential predictors of treatment success. This could lead to more personalized treatment strategies for lung cancer patients.

Why it matters

Where this research is happening

• University of California Los Angeles
  Los Angeles, United States Active

Researchers

• Principal investigator: Garon, Edward B — University of California Los Angeles
• Study coordinator: Garon, Edward B

Related research

Other NIH-funded projects on the same topics.

• HLA-B44 motif neoepitopes in NSCLC and how they affect the tumor environment

  This grant studies how specific tumor mutations and HLA-B44 genetic patterns influence response to PD-1 inhibitors in non-small cell lung cancer, with the goal of better predicting who benefits from immunotherapy.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11405014

• Using HLA-B44 tumor markers to predict lasting benefit from PD-1 therapy in lung cancer

  This project looks at whether specific tumor changes tied to the HLA-B44 gene can help predict which non-small cell lung cancer patients will have long-lasting responses to PD-1 immunotherapy, with or without chemotherapy.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11210786

• HLA-B44 genetic markers to predict long-term benefit from PD-1 immunotherapy in lung cancer

  This project looks at whether certain HLA-B44-related tumor changes can help predict which people with non-small cell lung cancer will get lasting benefit from PD‑1 immunotherapy with or without chemotherapy.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-11160793

• Investigating the effects of specific tumor markers in lung cancer treatment

  This study is looking at how certain genetic markers in people with non-small cell lung cancer might affect their response to a type of immunotherapy called PD-1 inhibitors, so we can better understand which patients could benefit the most from this treatment.

  NIH research University of California Los Angeles · Los Angeles, United States · NIH-10894083

• Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer

  A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.

  NIH research Utah State Higher Education System--University of Utah · Salt Lake City, United States · NIH-11601571

• 7-marker protein test to predict NSCLC response to anti-PD-1 therapy

  A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11552207

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.